Linked Life Data

19121766

Source:http://linkedlifedata.com/resource/pubmed/id/19121766

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-1-5
pubmed:abstractText
Establishing solutes that accumulate in body fluids in renal insufficiency as authentic uremic toxins is a process demanding in vitro and in vivo animal experiments as well as observational and interventional studies in humans. Asymmetric dimethylarginine (ADMA) is listed among the few uremic solutes close to the inference criteria for causal involvement into the pathogenesis of the uremic syndrome. In healthy subjects, the intravenous administration of this methylarginine, such as to bring circulating ADMA to supraphysiologic concentration, raises peripheral vascular resistances and arterial pressure. In uremic patients, ADMA is strongly associated with carotid atherosclerosis and with overall and cardiovascular mortality. Yet we still need the decisive proof that this substance is causally involved in the high risk of death and cardiovascular complications of this population-that is, an intervention study proving that reducing ADMA levels translates into better clinical outcomes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1532-8503
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
25-8
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
pubmed:affiliation
Renal and Transplantation Unit, Ospedali Riuniti, and CNR-IBIM, Reggio Cal., Iitaly.
pubmed:publicationType
Journal Article